A minor increase in injections in patients with DME is expected, given improvements in antidiabetic treatment and early detection of DME during the past 10 years due to the increase in patients with diabetes.4,5 A recent study6 of patients with nAMD revealed a projected linear growth of the number of patients with nAMD requiring VEGF inhibitors. This evidence concerns the gene VEGFA and diabetes mellitus.